Biogen Plunges as Forecast Cut, Top Drugs Sales Disappoint

July 2015
MondayMorning;7/27/2015, Vol. 23 Issue 27, p1
The article focuses on the growth in sales, revenue, and earnings of Biogen Inc., a biotechnology company, in 2015 while the company's sales for multiple-sclerosis drug Tecfidera has declined. Topics discussed include the expectation of the company to post its per-share earnings, the safety concerns related to Tecfidera, and a warning issued by the U.S. Food and Drug Administration on the death of a patient who took Tecfidera.


Related Articles

  • Biogen Idec Excels on Tecidera Launch. Shaffer, Catherine // BioWorld Today;7/26/2013, Vol. 24 Issue 142, p1 

    The article reports on the sales of the multiple sclerosis (MS) drug Tecfidera by biopharmaceutical firm Biogen Idec Inc. in the second quarter of 2013. It mentions that the outstanding sales of the drug has contributed 192 million dollars to the total revenues of the company for the quarter....

  • MS pills are making news.  // Inside MS;Feb/Mar2007, Vol. 25 Issue 1, p28 

    The article focuses on the development of several multiple sclerosis (MS) drugs in the U.S. Serono announced that the drug oral cladribine had been designated a fast-track product by the U.S. Food and Drug Administration. New data from an extension phase after an initial six-month phase 2 trial...

  • Acorda/Biogen Idec: pricing will determine success of symptomatic MS therapy.  // PharmaWatch: Biotechnology;Mar2010, Vol. 9 Issue 3, p10 

    The article reports on the approval of Ampyra from Acorda Therapeutics Inc. and Biogen Idec Inc. for the symptomatic treatment of multiple sclerosis by the U.S. Food and Drug Administration (FDA). It is said that the treatment is the first symptomatic option to be approved by the FDA for...

  • FDA Approves AVONEX(r) PEN(tm) and Dose Titration Regimen.  // Biomedical Market Newsletter;2/28/2012, Vol. 21, p1 

    The article provides information on an announcement made by Biogen Idec Inc., regarding the approval of its drug AVONEX (®) PEN (™) and Dose Titration Regimen by the U.S. Food and Drug Administration. AVONEX PEN is the first intramuscular (IM) autoinjector approved for the treatment of...

  • Biogen Idec Offers New MS Treatment Option.  // Chain Drug Review;4/22/2013, Vol. 35 Issue 7, p232 

    The article reports that the pharmaceutical company Biogen Idec Inc. is costing 54,900 dollars a year for the manufacturing of its multiple sclerosis drug Tecfidera which has received an approval from the U.S. Food and Drug Administration.

  • Biogen IDEC Grows on Sales, Rises on BG-12 Data as Well. Breindl, Anette // BioWorld Today;4/22/2011, Vol. 22 Issue 78, p1 

    The article reports on the financial performance of Biogen Idec for the first quarter of 2011. The company posted a 9% increase in revenues during the quarter. It outlines the rate of increase in sales posted by the company's multiple sclerosis drug Tysabri (natalizumab) and its other MS drug...

  • MS Drug Gets Priority Review.  // Chemical Market Reporter;7/5/2004, Vol. 266 Issue 1, p12 

    Reports on the move of the U.S. Food and Drug Administration to assign a priority review status to the biologics license application from Biogen Idec Inc. and Elan Corp. PLC. Use of the drug in treating multiple sclerosis; Submission of the application by the companies to the administration;...

  • Biogen Idec, Elan Release Antegren Results for Approval.  // Chemical Market Reporter;11/15/2004, Vol. 266 Issue 17, p14 

    Reports on the release of the results of a late-stage trial of Antegren or natalizumab, a multiple sclerosis treatment developed by Biogen IDEC and Elan Corp. PLC in November 2004. Preparation for the U.S. Food and Drug Administration's final review of the drug; Composition of the drug; Safety...

  • New Treatment for Multiple Sclerosis.  // FDA Consumer;Jan/Feb2005, Vol. 39 Issue 1, p6 

    Reports on a license given by the U.S. Food and Drug Authority to the Tysabri monoclonal antibody manufactured by Biogen Idec Inc. in 2004. Use of the drug in treating multiple sclerosis; Administration of the drug; Information on monoclonal antibodies; Function of Tysabri; Results of a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics